BC Court of Appeal clears way for opioid class action trial set for 2028
British Columbia’s opioid class action will proceed to a jury trial in February 2028 after the Court of Appeal dismissed the last pharmaceutical appeals, allowing the province to seek recovery of public health costs.
The British Columbia government’s multi-provincial opioid class action will go to trial after the province’s Court of Appeal unanimously rejected the remaining appeals by drug makers and distributors late last month. The ruling removes a final obstacle that had prevented the long-running litigation from moving forward and cements a trial date at the end of February 2028. The opioid class action, launched in 2018 on behalf of several provincial governments, seeks both compensation for health-care costs and accountability for marketing practices linked to the overdose crisis.
Court of Appeal decision and trial scheduling
The provincial Court of Appeal handed down a unanimous decision rejecting the last procedural challenges from pharmaceutical defendants, effectively preserving the class-action certification. With the appeals dismissed, the legal timetable now directs the case to begin its trial phase in late February 2028, roughly a decade after the province first filed suit. Government lawyers signalled they will push ahead to a full hearing of the substantive claims rather than pursue additional interlocutory litigation.
Scope and targets of the lawsuit
The action names a wide group of defendants, including opioid manufacturers, national distributors and consulting firms involved in the marketing and sale of opioid products. British Columbia brought the claim on behalf of multiple governments, arguing the industry’s conduct played a central role in creating and sustaining the province’s overdose emergency. The litigation frames those practices as a systemic campaign that increased opioid prescriptions and contributed to widespread addiction and overdose harms.
Province’s goals: recover costs and force accountability
At the heart of the suit are two stated objectives: recovery of taxpayer-funded health-care expenses tied to opioid harms, and public accountability for corporate conduct that allegedly misled prescribers and patients. The province has said the action is intended to recoup the costs borne by emergency departments, hospital care and addiction-treatment services while also seeking remedies that would change industry behaviour. Attorney General Niki Sharma described the recent appellate wins as further steps toward securing redress for families and communities affected by the crisis.
Legislative backdrop and legal framework
Following early settlements and ongoing litigation, the provincial government enacted legislation designed to create a legal mechanism for recovering opioid-related health-care costs and damages. That statutory framework is intended to support the province’s claims by clarifying how public expenditures linked to opioid use can be quantified and recovered. Lawyers for British Columbia also plan to rely on comparable statutes that other provinces have adopted when calculating aggregate damages and tracing responsibility across jurisdictions.
Purdue Pharma settlement and its influence
One of the most significant pre-trial developments was Purdue Pharma’s 2022 settlement, in which the company agreed to pay $150 million to resolve certain claims. While that agreement did not resolve the broader litigation against other manufacturers and distributors, it provided an early benchmark for recovery and reinforced the province’s contention that corporate settlements are an appropriate remedy. Legal analysts say the Purdue agreement helped justify legislative and litigation strategies by demonstrating that manufacturers can be held financially accountable.
Potential damages and methods of calculation
Provincial legal advisers have estimated that, if the court upholds the province’s claims in full, recoveries could reach into the billions of dollars, reflecting prolonged health-care spending across Canada. The province intends to use a combination of statutory recovery rules, cost-accounting models and expert evidence to quantify expenditures attributable to opioid prescribing and use. Defence teams are expected to challenge both liability and causation, arguing that other factors — including illicit drug supply and local health determinants — also drive overdose statistics.
Remaining hurdles and next steps
Despite the appellate clearance, lawyers on both sides acknowledge the path to final judgment will remain legally and logistically complex. The case could encounter additional procedural skirmishes, expert disputes and scheduling delays before and even during the trial. Provincial counsel have said they are taking active steps to keep the matter on track for the February 2028 start date, while defendants have signalled they will continue to mount vigorous defences.
The upcoming trial will test long-standing allegations about industry marketing and regulatory oversight and determine whether governments can recover pandemic-era and pre‑pandemic health-care costs associated with opioids. The proceeding promises to be one of the most consequential corporate-liability trials in Canada, with implications for provincial finances, public-health policy and how pharmaceutical conduct is regulated going forward.
